abrdn plc Invests $1.29 Million in G1 Therapeutics, Inc. (NASDAQ:GTHX)

abrdn plc acquired a new stake in G1 Therapeutics, Inc. (NASDAQ:GTHX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 423,869 shares of the company’s stock, valued at approximately $1,293,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Algert Global LLC purchased a new position in G1 Therapeutics during the 3rd quarter valued at about $98,000. Curi Wealth Management LLC grew its holdings in shares of G1 Therapeutics by 17.8% in the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock valued at $102,000 after purchasing an additional 10,700 shares in the last quarter. Creative Financial Designs Inc. ADV increased its stake in G1 Therapeutics by 98.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after buying an additional 17,475 shares during the period. Acadian Asset Management LLC acquired a new stake in G1 Therapeutics during the 3rd quarter worth approximately $189,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in G1 Therapeutics by 68.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock valued at $294,000 after buying an additional 82,879 shares during the period. Hedge funds and other institutional investors own 24.21% of the company’s stock.

G1 Therapeutics Stock Performance

Shares of GTHX stock opened at $3.72 on Tuesday. G1 Therapeutics, Inc. has a 12 month low of $1.08 and a 12 month high of $5.00. The company has a current ratio of 3.87, a quick ratio of 3.45 and a debt-to-equity ratio of 1.46. The company has a market cap of $194.31 million, a P/E ratio of -3.92 and a beta of 1.73. The firm has a fifty day moving average price of $3.78 and a 200 day moving average price of $3.02.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. The business had revenue of $14.87 million for the quarter, compared to the consensus estimate of $12.83 million. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. During the same quarter in the prior year, the business posted ($0.73) EPS. Sell-side analysts predict that G1 Therapeutics, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Buying and Selling at G1 Therapeutics

In other news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the transaction, the insider now owns 169,938 shares in the company, valued at approximately $785,113.56. The sale was disclosed in a document filed with the SEC, which is available at this link. 8.23% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on GTHX. Wedbush reiterated an “outperform” rating and issued a $5.00 price objective (up from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th. Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of G1 Therapeutics in a research report on Friday, April 12th.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.